Inaganti Shah, MD
Hematology & Oncology · Omaha, NENPI 1295829042
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in NE, where the typical reported total is $3,016.
Across 68 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$143
- Merck$137
- E.r. Squibb & Sons, L.L.C.$118
- AbbVie$112
- Pfizer$103
- Genentech USA, Inc.$91
- plus $661 from 23 others
What the payments were for
- Food & beverage$1,28694%
- Education$796%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 5 | $143 |
| Merck | 7 | $137 |
| E.r. Squibb & Sons, L.L.C. | 6 | $118 |
| AbbVie | 5 | $112 |
| Pfizer | 5 | $103 |
| Genentech USA, Inc. | 5 | $91 |
| Lilly USA, LLC | 5 | $81 |
| Novartis | 3 | $57 |
| GSK | 3 | $50 |
| Eisai Inc. | 2 | $38 |
| AVEO Pharmaceuticals, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 1 | $34 |
| Beone Medicines USA, Inc. | 1 | $34 |
| AstraZeneca | 2 | $32 |
| Gilead | 2 | $27 |
| Octapharma USA, Inc. | 1 | $25 |
| Pharming Healthcare, Inc. | 1 | $25 |
| Geron Corporation | 1 | $24 |
| Blueprint Medicines Corporation | 1 | $21 |
| Syndax Pharmaceuticals, Inc. | 1 | $21 |
| Sanofi | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Servier Pharmaceuticals LLC | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Bayer | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $17 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $16 |
| Exelixis Inc. | 1 | $14 |
| Array Biopharma Inc | 1 | $13 |
How this compares
$1,364 in reported general payments places this provider in the 30th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 29 | $452,770 |
| Lenalidomide | 19 | $227,048 |
| RevlimidLenalidomide | 14 | $204,318 |
| BrukinsaZanubrutinib | 13 | $174,205 |
| XtandiEnzalutamide | 11 | $157,768 |
| VenclextaVenetoclax | 13 | $96,303 |
| Abiraterone Acetate | 50 | $46,080 |
| EliquisApixaban | 35 | $32,303 |
| XareltoRivaroxaban | 19 | $10,732 |
| Anastrozole | 82 | $1,148 |
| Hydroxyurea | 18 | $614 |
| Tamoxifen Citrate | 29 | $601 |
| Ondansetron Hcl | 50 | $599 |
| Dexamethasone | 62 | $527 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $16 | $452,77029 claims |
| Astellas Pharma US IncXtandi | $34 | $157,76811 claims |
| AbbVieVenclexta | $112 | $96,30313 claims |
| PfizerEliquis | $103 | $32,30335 claims |
| Lilly USA, LLCOlanzapine | $81 | $15722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Omaha
- Mojtaba AkhtariOmaha$1.8M
- Luke NordquistOmaha$202K
- Apar Kishor GantiOmaha$138K
- Julie VoseOmaha$123K
- Peter SilbersteinOmaha$99K
- Krishna GundaboluOmaha$76K
- Vijaya BhattOmaha$58K
- Samer RennoOmaha$41K
- Timothy DoriusOmaha$24K
- Stefano TarantoloOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.